The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.
Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Self-citationZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Self-citationKieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.
Jang, H.-J., Kokrashvili, Z., Theodorakis, M. J., Carlson, O. D., Kim, B.-J., Zhou, J., Kim, H. H., Xu, X., Chan, S. L., Juhaszova, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706890104 · Cited by 995
Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Aschner, P., Kipnes, M. S., Lunceford, J. K., Sanchez, M., Mickel, C., Williams-Herman, D. E., & for the Sitagliptin Study 021 Group (2006) · Diabetes Care · doi:10.2337/dc06-0703 · Cited by 880
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Self-citationDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Sherwood, N. M., Krueckl, S. L., & McRory, J. E. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0414 · Cited by 726
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Nauck, M. A., Meininger, G., Sheng, D., Terranella, L., Stein, P. P., & Sitagliptin Study 024 Group (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00704.x · Cited by 667
Self-citationFarilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654
Augeri, D. J., Robl, J. A., Betebenner, D. A., Magnin, D. R., Khanna, A., Robertson, J. G., Wang, A., Simpkins, L. M., Taunk, P., Huang, Q., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050261p · Cited by 624
Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Bergenstal, R. M., Wysham, C., MacConell, L., Malloy, J., Walsh, B., Yan, P., Wilhelm, K., Malone, J., & Porter, L. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60590-9 · Cited by 608
Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605
Self-citationVerdich, C., Flint, A., Gutzwiller, J.-P., Näslund, E., Beglinger, C., Hellström, P. M., Long, S. J., Morgan, L. M., Holst, J. J., & Astrup, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7877 · Cited by 600
Herrmann, C., Göke, R., Richter, G., Fehmann, H.-C., Arnold, R., & Göke, B. (2009) · Digestion · doi:10.1159/000201231 · Cited by 597
Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595
Holz IV, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 594
Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586
Self-citationEnhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Stoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Glucagon-like peptide-1: a potent regulator of food intake in humans
Gutzwiller, J.-P., Göke, B., Drewe, J., Hildebrand, P., Ketterer, S., Handschin, D., Winterhalder, R., Conen, D., & Beglinger, C. (1999) · Gut · doi:10.1136/gut.44.1.81 · Cited by 576
Brubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 540
FEHMANN, H.-C., GÖKE, R., & GÖKE, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 528
Hermansen, K., Kipnes, M., Luo, E., Fanurik, D., Khatami, H., Stein, P., & Sitagliptin Study 035 Group (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00744.x · Cited by 525
Gutzwiller, J.-P., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 521
HERMAN, G., STEVENS, C., VANDYCK, K., BERGMAN, A., YI, B., DESMET, M., SNYDER, K., HILLIARD, D., TANEN, M., & TANAKA, W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.002 · Cited by 519
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Rosenstock, J., Brazg, R., Andryuk, P. J., Lu, K., & Stein, P. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.007 · Cited by 514
Nauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506
Self-citationWillms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Self-citationMu, J., Woods, J., Zhou, Y.-P., Roy, R. S., Li, Z., Zycband, E., Feng, Y., Zhu, L., Li, C., Howard, A. D., et al. (2006) · Diabetes · doi:10.2337/db05-1602 · Cited by 449
Bosi, E., Camisasca, R. P., Collober, C., Rochotte, E., & Garber, A. J. (2007) · Diabetes Care · doi:10.2337/dc06-1732 · Cited by 447
Incretins, insulin secretion and Type 2 diabetes mellitus
Vilsbøll, T., & Holst, J. J. (2004) · Diabetologia · doi:10.1007/s00125-004-1342-6 · Cited by 444
Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes
Noel, R. A., Braun, D. K., Patterson, R. E., & Bloomgren, G. L. (2009) · Diabetes Care · doi:10.2337/dc08-1755 · Cited by 435
Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427
Zinman, B., Hoogwerf, B. J., Durán García, S., Milton, D. R., Giaconia, J. M., Kim, D. D., Trautmann, M. E., & Brodows, R. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-7-200704030-00003 · Cited by 427
DeFronzo, R. A., Hissa, M. N., Garber, A. J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., Chen, R. S., & for the Saxagliptin 014 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1984 · Cited by 416
Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409
Deacon, C. F., Nauck, M. A., Meier, J., Hücking, K., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6855 · Cited by 401
Self-citationØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384
Intestinal Factors in the Control of Insulin Secretion
McINTYRE, N., HOLDSWORTH, C. D., & TURNER, D. S. (1965) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-25-10-1317 · Cited by 381
Orskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia
Xu, G., Kaneto, H., Laybutt, D. R., Duvivier-Kali, V. F., Trivedi, N., Suzuma, K., King, G. L., Weir, G. C., & Bonner-Weir, S. (2007) · Diabetes · doi:10.2337/db06-1033 · Cited by 377
DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802418851 · Cited by 373
Mari, A., Sallas, W. M., He, Y. L., Watson, C., Ligueros-Saylan, M., Dunning, B. E., Deacon, C. F., Holst, J. J., & Foley, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2460 · Cited by 361
Vollmer, K., Holst, J. J., Baller, B., Ellrichmann, M., Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2008) · Diabetes · doi:10.2337/db07-1124 · Cited by 356
Self-citationMoretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350
Toft-Nielsen, M. B., Madsbad, S., & Holst, J. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1137 · Cited by 338
Glucagon-like peptide-1 prevents beta cell glucolipotoxicity
Joly, E., Prentki, M., Buteau, J., El-Assaad, W., Rhodes, C. J., & Rosenberg, L. (2004) · Diabetologia · doi:10.1007/s00125-004-1379-6 · Cited by 337
Oravecz, T., Pall, M., Roderiquez, G., Gorrell, M. D., Ditto, M., Nguyen, N. Y., Boykins, R., Unsworth, E., & Norcross, M. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.11.1865 · Cited by 332
Dore, D. D., Seeger, J. D., & Arnold Chan, K. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902820519 · Cited by 326
Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes
Pi-Sunyer, F. X., Schweizer, A., Mills, D., & Dejager, S. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.12.009 · Cited by 312
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., & Lerch, C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006739.pub2 · Cited by 308
Deacon, C. F. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.10.3575 · Cited by 301
Ferrannini, E., Fonseca, V., Zinman, B., Matthews, D., Ahrén, B., Byiers, S., Shao, Q., & Dejager, S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00994.x · Cited by 297
Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.015 · Cited by 279
Schirra, J., Nicolaus, M., Roggel, R., Katschinski, M., Storr, M., Woerle, H. J., & Göke, B. (2006) · Gut · doi:10.1136/gut.2004.059741 · Cited by 277
Hare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J. (2010) · Diabetes · doi:10.2337/db09-1414 · Cited by 276
Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276
Self-citationØrskov, C., Wettergren, A., & Holst, J. J. (1996) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529609009147 · Cited by 271
Rachman, J., Barrow, B. A., Levy, J. C., & Turner, R. C. (1997) · Diabetologia · doi:10.1007/s001250050664 · Cited by 269
Garber, A. J., Schweizer, A., Baron, M. A., Rochotte, E., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00684.x · Cited by 268
Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Raz, I., Chen, Y., Wu, M., Hussain, S., Kaufman, K. D., Amatruda, J. M., Langdon, R. B., Stein, P. P., & Alba, M. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x260925 · Cited by 260
Williams-Herman, D., Engel, S. S., Round, E., Johnson, J., Golm, G. T., Guo, H., Musser, B. J., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2010) · BMC Endocrine Disorders · doi:10.1186/1472-6823-10-7 · Cited by 258
De Marinis, Y. Z., Salehi, A., Ward, C. E., Zhang, Q., Abdulkader, F., Bengtsson, M., Braha, O., Braun, M., Ramracheya, R., Amisten, S., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.007 · Cited by 257
Sokos, G. G., Bolukoglu, H., German, J., Hentosz, T., Magovern, G. J., Maher, T. D., Dean, D. A., Bailey, S. H., Marrone, G., Benckart, D. H., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.022 · Cited by 252
Burcelin, R., Da Costa, A., Drucker, D., & Thorens, B. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1720 · Cited by 250
Matveyenko, A. V., Dry, S., Cox, H. I., Moshtaghian, A., Gurlo, T., Galasso, R., Butler, A. E., & Butler, P. C. (2009) · Diabetes · doi:10.2337/db09-0058 · Cited by 242
Gedulin, B. R., Nikoulina, S. E., Smith, P. A., Gedulin, G., Nielsen, L. L., Baron, A. D., Parkes, D. G., & Young, A. A. (2005) · Endocrinology · doi:10.1210/en.2004-1349 · Cited by 242
What do we know about the secretion and degradation of incretin hormones?
Deacon, C. F. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.007 · Cited by 241
Schweizer, A., Couturier, A., Foley, J. E., & Dejager, S. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02191.x · Cited by 240
Chacra, A. R., Tan, G. H., Apanovitch, A., Ravichandran, S., List, J., Chen, R., & for the CV181-040 Investigators (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02143.x · Cited by 237
Garber, A. J., Foley, J. E., Banerji, M. A., Ebeling, P., Gudbjörnsdottir, S., Camisasca, R. ‐., Couturier, A., & Baron, M. A. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00859.x · Cited by 230
Meier, J. J., Hücking, K., Holst, J. J., Deacon, C. F., Schmiegel, W. H., & Nauck, M. A. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2497 · Cited by 230
Self-citationGreen, B. D., Flatt, P. R., & Bailey, C. J. (2006) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2006.024 · Cited by 223
Scott, R., Loeys, T., Davies, M. J., Engel, S. S., & for the Sitagliptin Study 801 Group (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00839.x · Cited by 223
Meier, J. J., & Nauck, M. A. (2010) · Diabetes · doi:10.2337/db09-1899 · Cited by 215
Self-citationVilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213
Girman, C. J., Kou, T. D., Cai, B., Alexander, C. M., O’Neill, E. A., Williams‐Herman, D. E., & Katz, L. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01231.x · Cited by 212
Buchan, A. M. J., Polak, J. M., Capella, C., Solcia, E., & Pearse, A. G. E. (1978) · Histochemistry · doi:10.1007/bf00492251 · Cited by 210
Mistry, G. C., Maes, A. L., Lasseter, K. C., Davies, M. J., Gottesdiener, K. M., Wagner, J. A., & Herman, G. A. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008316885 · Cited by 209
Sturis, J., Gotfredsen, C. F., Rømer, J., Rolin, B., Ribel, U., Brand, C. L., Wilken, M., Wassermann, K., Deacon, C. F., Carr, R. D., et al. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705397 · Cited by 202
Reimer, M., Holst, J., & Ahren, B. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460717 · Cited by 195
Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?
McIntosh, C. H. S., Demuth, H.-U., Pospisilik, J. A., & Pederson, R. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.001 · Cited by 192
Havale, S. H., & Pal, M. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.01.061 · Cited by 190
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
Nauck, M. A., & Meier, J. J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.014 · Cited by 180
Self-citationBuse, J. B., Sesti, G., Schmidt, W. E., Montanya, E., Chang, C.-T., Xu, Y., Blonde, L., Rosenstock, J., & for the Liraglutide Effect Action in Diabetes (LEAD)-6 Study Group (2010) · Diabetes Care · doi:10.2337/dc09-2260 · Cited by 177
Chia, C. W., Carlson, O. D., Kim, W., Shin, Y.-K., Charles, C. P., Kim, H. S., Melvin, D. L., & Egan, J. M. (2009) · Diabetes · doi:10.2337/db08-0958 · Cited by 176
Qualmann, C., Nauck, M. A., Holst, J. J., øSrskov, C., & Creutzfeldt, W. (1995) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529509101597 · Cited by 170
Self-citationThe long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro
Bregenholt, S., Møldrup, A., Blume, N., Karlsen, A. E., Friedrichsen, B. N., Tornhave, D., Knudsen, L. B., & Petersen, J. S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.013 · Cited by 170
Unraveling the Science of Incretin Biology
Nauck, M. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.012 · Cited by 168
Self-citationFlentke, G. R., Munoz, E., Huber, B. T., Plaut, A. G., Kettner, C. A., & Bachovchin, W. W. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.4.1556 · Cited by 168
Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes
Nauck, M. A., Baller, B., & Meier, J. J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s190 · Cited by 163
Self-citationNäslund, E., King, N., Mansten, S., Adner, N., Holst, J. J., Gutniak, M., & Hellström, P. M. (2004) · British Journal of Nutrition · doi:10.1079/bjn20031064 · Cited by 160
GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats
Qin, X., Shen, H., Liu, M., Yang, Q., Zheng, S., Sabo, M., D’Alessio, D. A., & Tso, P. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00303.2004 · Cited by 160
Hanefeld, M., Herman, G. A., Wu, M., Mickel, C., Sanchez, M., Stein, P. P., & on behalf of the Sitagliptin Study 014 investigators (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x188152 · Cited by 160
He, H., Tran, P., Yin, H., Smith, H. T., Batard, Y., Wang, L., Einolf, H. J., Gu, H., Mangold, J. B., Fischer, V., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023010 · Cited by 160
Schön, E., Jahn, S., Kießig, S. T., Demuth, H., Neubert, K., Barth, A., von Baehr, R., & Ansorge, S. (1987) · European Journal of Immunology · doi:10.1002/eji.1830171222 · Cited by 150
Deacon, C. F., Wamberg, S., Bie, P., Hughes, T., & Holst, J. J. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1720355 · Cited by 147
Holst, J. J. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(99)00157-5 · Cited by 146
Cleator, I. G. M., & Gourlay, R. H. (1975) · The American Journal of Surgery · doi:10.1016/0002-9610(75)90360-8 · Cited by 141
The pathogenesis of NIDDM involves a defective expression of the GIP receptor
Holst, J. J., Gromada, J., & Nauck, M. A. (1997) · Diabetologia · doi:10.1007/s001250050779 · Cited by 136
Self-citationHypersecretion of Gastric Inhibitory Polypeptide Following Oral Glucose in Diabetes Mellitus
Ross, S. A., Brown, J. C., & Dupré, J. (1977) · Diabetes · doi:10.2337/diab.26.6.525 · Cited by 135
Deacon, C. F., & Holst, J. J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903463862 · Cited by 131
Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes
Salehi, M., Aulinger, B., Prigeon, R. L., & D'Alessio, D. A. (2010) · Diabetes · doi:10.2337/db09-1253 · Cited by 124
El-Ouaghlidi, A., Rehring, E., Holst, J. J., Schweizer, A., Foley, J. E., Holmes, D., & Nauck, M. A. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1932 · Cited by 120
Self-citationThe Incretin Approach for Diabetes Treatment
Holst, J. J., & Ørskov, C. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s197 · Cited by 119
Nauck, M. A., Sauerwald, A., Ritzel, R. A., Holst, J. J., & Schmiegel, W. (1998) · Diabetes Care · doi:10.2337/diacare.21.11.1925 · Cited by 113
Self-citationQuddusi, S., Vahl, T. P., Hanson, K., Prigeon, R. L., & D’Alessio, D. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.791 · Cited by 111
Åhrén, B., & Hughes, T. E. (2004) · Endocrinology · doi:10.1210/en.2004-1174 · Cited by 111
Salehi, M., Vahl, T. P., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0605 · Cited by 108
Neural regulation of glucagon-like peptide-1 secretion in pigs
Hansen, L., Lampert, S., Mineo, H., & Holst, J. J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00197.2004 · Cited by 106
Exenatide inhibits β-cell apoptosis by decreasing thioredoxin-interacting protein
Chen, J., Couto, F. M., Minn, A. H., & Shalev, A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.027 · Cited by 106
Incretins and the development of type 2 diabetes
Meier, J. J., & Nauck, M. A. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0034-7 · Cited by 105
Self-citationHildebrandt, M., Reutter, W. G., Arck, P., Rose, M., & Klapp, B. F. (2000) · Clinical Science · doi:10.1042/cs0990093 · Cited by 104
Pharmacological Characterization of Human Incretin Receptor Missense Variants
Fortin, J., Schroeder, J. C., Zhu, Y., Beinborn, M., & Kopin, A. S. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160531 · Cited by 99
Bulotta, A., Hui, H., Anastasi, E., Bertolotto, C., Boros, L. G., Mario, U. D., & Perfetti, R. (2002) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0290347 · Cited by 96
Meier, J. J., Gallwitz, B., Kask, B., Deacon, C. F., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s220 · Cited by 92
Self-citationJones, I. R., Owens, D. R., Luzio, S. D., Williams, S. E. I., & Hayes, T. M. (1989) · Diabetologia · doi:10.1007/bf00274255 · Cited by 91
Substance P: transmitter of nociception (Minireview).
Zubrzycka, M., & Janecka, A. E. (2000) · PubMed · Cited by 91
The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1
Nauck, M. A., & El-Ouaghlidi, A. (2005) · Diabetologia · doi:10.1007/s00125-005-1704-8 · Cited by 90
Self-citationDPP‐IV inhibition enhances the antilipolytic action of NPY in human adipose tissue
Kos, K., Baker, A. R., Jernås, M., Harte, A. L., Clapham, J. C., O’Hare, J. P., Carlsson, L. M. S., Kumar, S., & McTernan, P. G. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00909.x · Cited by 83
Glucagon-Like Peptide 1 Regulates Sequential and Compound Exocytosis in Pancreatic Islet β-Cells
Kwan, E. P., & Gaisano, H. Y. (2005) · Diabetes · doi:10.2337/diabetes.54.9.2734 · Cited by 77
CHILTON, R. J., Wyatt, J., Nandish, S., OLIVEROS, R. A., & Lujan, M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.004 · Cited by 72
Kubota, A., Yamada, Y., HAYAMI, T., Yasuda, K., Someya, Y., Ihara, Y., Kagimoto, S., Watanabe, R., Taminato, T., Tsuda, K., et al. (1996) · Diabetes · doi:10.2337/diab.45.12.1701 · Cited by 62
Grouzmann, E., Monod, M., Landis, B. N., Wilk, S., Brakch, N., Nicoucar, K., Giger, R., Malis, D. D., Szalay‐Quinodoz, I., Cavadas, C., et al. (2002) · The FASEB Journal · doi:10.1096/fj.01-0939fje · Cited by 59
Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Gilbert, M. P., & Pratley, R. E. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.013 · Cited by 58
Inhibition of dipeptidyl peptidase IV activity as a therapy of Type 2 diabetes
Green, B. D., Flatt, P. R., & Bailey, C. J. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.3.525 · Cited by 53
Nauck, M. A., Weber, I., Bach, I., Richter, S., Ørskov, C., Holst, J. J., & Schmiegel, W. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(1998110)15:11<937::aid-dia701>3.0.co;2-0 · Cited by 53
Self-citationThe contribution of incretin hormones to the pathogenesis of type 2 diabetes
Meier, J. J. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.007 · Cited by 46
Impact of Sitagliptin on Markers of β-cell Function: A Meta-Analysis
Riche, D. M., East, H. E., & Riche, K. D. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31818eb721 · Cited by 44
Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?
Meier, J. J., & Nauck, M. A. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0946 · Cited by 41
Self-citationLarsen, M. O., Rolin, B., Ribel, U., Wilken, M., Deacon, C. F., Svendsen, O., Gotfredsen, C. F., & Carr, R. D. (2003) · Journal of Diabetes Research · doi:10.1155/edr.2003.93 · Cited by 21
Bergmann, A., & Bohuon, C. (2002) · Clinica Chimica Acta · doi:10.1016/s0009-8981(02)00042-6 · Cited by 18
Meier, S., Hücking, K., Ritzel, R. A., Holst, J. J., Schmiegel, W., & Nauck, M. A. (2003) · Hormone and Metabolic Research · doi:10.1055/s-2003-42658 · Cited by 18
Self-citationGlucagon‐like peptide‐1 in type 2 diabetes: the β‐cell and beyond
Nauck, M. A. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00919.x · Cited by 14
Self-citationEfficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis
Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12
Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_12 · Cited by 5
Self-citationØrskov, C., Hjorth, S. A., Jensen, A. D., & Vilsbøll, T. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.03.007 · Cited by 3
Cited by
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationManagement of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Self-citationAdipokines in health and disease
Fasshauer, M., & Blüher, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.014 · Cited by 1,050
Bile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935
“Because GLP-1 mimetic and receptor agonists have shown promise in improving glucose homeostasis in diabetes, bile acid–based TGR5 agonists may be used to stimulate GLP-1 secretion in diabetic patients (Nauck, 2011).”
Background
Metadata
- Authors
- Nauck, M. A.
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 124
- Issue
- 1
- Pages
- S3-S18
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2064437324
- Cited by
- 295
- References
- 175
- FWCI
- 22.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.